EV/EBITDA - WuXi Biologics (Cayman) Inc (HKEX:2269) - Alpha Spread

WuXi Biologics (Cayman) Inc
HKEX:2269

Watchlist Manager
WuXi Biologics (Cayman) Inc Logo
WuXi Biologics (Cayman) Inc
HKEX:2269
Watchlist
Price: 11.06 HKD -0.18% Market Closed
Market Cap: 45.9B HKD
Have any thoughts about
WuXi Biologics (Cayman) Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

7.3
Current
40.2
Median
19.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
7.3
=
Enterprise Value
39.3B HKD
/
EBITDA
4.9B CNY
All Countries
Close

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
5.5
2-Years Forward
EV/EBITDA
4.8
3-Years Forward
EV/EBITDA
4.2

See Also

Discover More